

# Maha H A Hussain

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7362989/publications.pdf>

Version: 2024-02-01

84  
papers

16,757  
citations

117625

34  
h-index

64796

79  
g-index

85  
all docs

85  
docs citations

85  
times ranked

14534  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). <i>Clinical Cancer Research</i> , 2022, 28, 1518-1530.	7.0	41
2	Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 441-448.	1.3	9
3	Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 393-405.	10.7	16
4	Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 13-13.	1.6	7
5	Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1132-1142.	27.0	341
6	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. <i>Journal of Clinical Oncology</i> , 2022, 40, 3011-3014.	1.6	12
7	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	1.9	51
8	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). <i>Journal of Clinical Oncology</i> , 2022, 40, 3301-3309.	1.6	14
9	Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHARTED E3805. <i>Prostate</i> , 2022, 82, 1176-1185.	2.3	2
10	Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial. <i>Future Oncology</i> , 2022, 18, 2585-2597.	2.4	3
11	Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5078-5078.	1.6	10
12	Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?. <i>Journal of Clinical Oncology</i> , 2021, 39, 13-16.	1.6	9
13	Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 558-566.	3.9	9
14	Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in <i>BRCA1</i> , <i>BRCA2</i> or <i>ATM</i> : Results from the PROfound study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 27-27.	1.6	17
15	Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.. <i>Journal of Clinical Oncology</i> , 2021, 39, 126-126.	1.6	11
16	Re: Konrad H. Stoopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2020.09.024">https://doi.org/10.1016/j.eururo.2020.09.024</a> . <i>European Urology</i> , 2021, 79, e83-e84.	1.9	0
17	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3017-3027.	7.0	19
18	Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Targeted Oncology</i> , 2021, 16, 613-623.	3.6	6

#	ARTICLE	IF	CITATIONS
19	Editorial Comment. Journal of Urology, 2021, 206, 628-629.	0.4	0
20	Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy. Urology Case Reports, 2021, 38, 101657.	0.3	1
21	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer and Prostatic Diseases, 2021, , .	3.9	2
22	The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers, 2021, 13, 5872.	3.7	3
23	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European Journal of Cancer, 2021, 159, 237-246.	2.8	6
24	PARP Inhibition in Advanced Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2021, 27, 457-464.	2.0	3
25	Accelerating precision medicine in metastatic prostate cancer. Nature Cancer, 2020, 1, 1041-1053.	13.2	45
26	EDITORIAL COMMENT. Urology, 2020, 146, 165-166.	1.0	0
27	Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHARTED Trial. European Urology Oncology, 2020, 3, 717-724.	5.4	15
28	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 383, 2345-2357.	27.0	440
29	Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. JAMA Oncology, 2020, 6, 1793.	7.1	10
30	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 382, 2197-2206.	27.0	253
31	Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 486-493.	3.9	4
32	Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 382, 2091-2102.	27.0	1,327
33	Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer. European Urology, 2020, 78, 193-194.	1.9	5
34	<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precision Oncology, 2020, 4, 370-381.	3.0	138
35	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naïve Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 332-339.e2.	1.9	5
36	Impact of olaparib vs physician's choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.. Journal of Clinical Oncology, 2020, 38, 5538-5538.	1.6	1

#	ARTICLE	IF	CITATIONS
37	PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. Journal of Clinical Oncology, 2020, 38, 134-134.	1.6	6
38	Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.. Journal of Clinical Oncology, 2020, 38, 195-195.	1.6	11
39	EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells. Cell Death and Disease, 2019, 10, 801.	6.3	38
40	Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?. Translational Andrology and Urology, 2019, 8, S91-S92.	1.4	0
41	Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order"? European Urology Focus, 2019, 5, 125-133.	3.1	4
42	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2019, 20, 556-569.	10.7	90
43	Inflammatory Bowel Disease and the Risk of Prostate Cancer. European Urology, 2019, 75, 846-852.	1.9	47
44	Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate, 2018, 78, 121-127.	2.3	28
45	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. Journal of Clinical Oncology, 2018, 36, 937-941.	1.6	7
46	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. Journal of Clinical Oncology, 2018, 36, 376-382.	1.6	75
47	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1088-1095.	1.6	72
48	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology, 2018, 36, 991-999.	1.6	169
49	Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. Journal of Clinical Oncology, 2018, 36, 1498-1504.	1.6	34
50	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHARTED Trial. Journal of Clinical Oncology, 2018, 36, 1080-1087.	1.6	702
51	Enzalutamide in Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2018, 379, 1380-1381.	27.0	10
52	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2018, 378, 2465-2474.	27.0	782
53	Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2018, 36, 251-251.	1.6	4
54	ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2018, 36, TPS383-TPS383.	1.6	18

#	ARTICLE	IF	CITATIONS
55	Effect of bypass kinase pathways on acquired CDK4/6 inhibitor resistance.. Journal of Clinical Oncology, 2018, 36, 379-379.	1.6	0
56	The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer, 2017, 123, 1912-1924.	4.1	52
57	Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncology, 2017, 3, e170231.	7.1	9
58	PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. Journal of Clinical Oncology, 2017, 35, TPS5091-TPS5091.	1.6	10
59	ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2017, 35, TPS5092-TPS5092.	1.6	0
60	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	27.0	1,205
61	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 2016, 34, 1402-1418.	1.6	1,089
62	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1652-1659.	1.6	332
63	Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. JAMA Oncology, 2016, 2, 453.	7.1	83
64	Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. Journal of Clinical Oncology, 2016, 34, 280-285.	1.6	42
65	Why Chemotherapy Should be Given Early for Men with Metastatic Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e263-e269.	3.8	1
66	Integrated Multimodal Imaging of Dynamic Bone-Tumor Alterations Associated with Metastatic Prostate Cancer. PLoS ONE, 2015, 10, e0123877.	2.5	9
67	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	28.9	2,660
68	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 2015, 373, 737-746.	27.0	2,112
69	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1601-1608.	1.6	44
70	Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. Journal of Urology, 2015, 194, 790-798.	0.4	85
71	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. Journal of Clinical Oncology, 2014, 32, 3391-3399.	1.6	110
72	Bladder preservationâ€”learning what we don't know. Nature Reviews Urology, 2014, 11, 310-312.	3.8	3

#	ARTICLE	IF	CITATIONS
73	Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen. <i>Clinical Cancer Research</i> , 2014, 20, 4218-4227.	7.0	29
74	Molecular Pathways: Targeting ETS Gene Fusions in Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4442-4448.	7.0	54
75	Non-castrate Metastatic Prostate Cancer: Have the Treatment Options Changed?. <i>Seminars in Oncology</i> , 2013, 40, 337-346.	2.2	20
76	Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 893-900.	10.7	139
77	Intermittent versus Continuous Androgen Deprivation in Prostate Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1314-1325.	27.0	482
78	Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer. <i>Molecular Medicine</i> , 2013, 19, 367-376.	4.4	24
79	Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. <i>Journal of Clinical Oncology</i> , 2009, 27, 2450-2456.	1.6	176
80	Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1148-1159.	1.6	1,960
81	Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162). <i>Journal of Clinical Oncology</i> , 2006, 24, 3984-3990.	1.6	417
82	Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2527-2533.	1.6	198
83	Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. <i>Investigational New Drugs</i> , 1997, 15, 99-108.	2.6	41
84	Inhibition of prostate cancer growth by estramustine and etoposide. <i>Cancer</i> , 1995, 75, 1920-1926.	4.1	8